A clinical study comparing topotecan plus carboplatin versus etoposide plus carboplatin for previ-ously untreated small cell lung cancer
- VernacularTitle:拓扑替康联合卡铂与足叶乙苷联合卡铂比较一线治疗小细胞肺癌临床研究
- Author:
Siliang WANG
;
Rong WU
;
Zhaoguo XU
;
Xiaodong CHEN
- Publication Type:Journal Article
- Keywords:
Carcinoma,small cell;
Topotecan;
Carboplatin
- From:
Chinese Journal of Postgraduates of Medicine
2008;31(15):4-6
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the efficacy and toxicity of topoteean hydllochloride plus carbo-platin(TC)versus etoposide plus carboplatin(CE)in patients for previously untreated small cell lung cancer (SCLC).Methods Sixty-nine patients with previously untreated SCLC,TC group(34 eases)were treated with topotecan 1 mg/m2 from day 1 to day 5 and carboplatin 300 mg/m2on day 1.CE group(35 cases)were treated with etoposide 100 mg/d from day 1 to day 5 and carboplatin 300 mg/m2 on day 1.Treatment was repeated every 3 weeks.The efficacy and toxicity were ev Mumed in patients who received two cvcles of chemotherapy.ResMN The total effective rate Was 76.5%in TC group and 71.4%in CE group(P＞0.05). The progression-free survival interval was 4.1 months in TC group and 2.6 months in CE group(P＜0.05). There was no significant difference in the most common toxieities between two groups(P＞0.05).Conclusion Compared with etoposide plus carboplatin,topotecan plus carboplatin has similar total effective rate,and in- different toxieities,and the longer progression-free survival interval,so it is a safe and effective first-line treatment for SCLC.
